Circulating interleukin‐6 concentration and cognitive decline in old age: the <scp>PROSPER</scp> study

Mooijaart, Simon P.; Sattar, Naveed; Trompet, Stella; Lucke, Jayne; Stott, David J.; Ford, Ian; Jukema, J. Wouter; Westendorp, Rudi G.J.; Craen, Anton J. M. de

doi:10.1111/joim.12052

Cited by 98 publications

(72 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results suggest that systemic IL-6 would only be suitable for cognitive risk stratification in the oldest old. Furthermore, the PROSPER study and a stratified analysis of the NOMAS study reported high IL-6 levels to be associated with an increased rate of detailed assessments of cognitive decline in individuals aged older than 75 or 71 years, respectively (Mooijaart et al 2013;Economos et al 2013). The relationship between inflammation and depression in old age is poorly understood but generally accepted, particularly because depression and dementia are strongly interrelated.…”

Section: Discussionmentioning

confidence: 99%

“…Likewise, CRP was often found to exhibit a lesser or non-significant association with physical decline (Stenholm et al 2010). The same holds for cognitive decline (Mooijaart et al 2013;Economos et al 2013;Schram et al 2007) and occurrence of depression symptoms (Bremmer et al 2008). Despite their biological connection, various pathways are proposed, as only a small correlation could be found between both measures (Pearson r= 0.15, p=0.003).…”

Section: Value Of Crp and Other Inflammatory Markersmentioning

confidence: 99%

“…Additionally, both IL-6 and C-reactive protein (CRP) were persistently associated with mortality risk in aging population studies (Singh and Newman 2011). The relationship between IL-6 or CRP and cognitive decline or occurrence of depressive symptoms has also been described in several population studies (Mooijaart et al 2013;Bremmer et al 2008).…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study

Adriaensen

Matheï

Vaes

et al. 2014

AGE

View full text Add to dashboard Cite

The chronic inflammatory state at old age may contribute to the pathophysiology of or reflect chronic conditions resulting in loss of physical and mental functioning. Therefore, our objective was to examine the predictive value of a large battery of serum inflammatory markers as risk indicators for global functional decline and its specific physical and mental determinants in the oldest old. Global functional decline and specific aspects of physical and mental functional decline were assessed during an average of 1.66 years (±0.21) in a sample of 303 persons aged 80 years or older of the BELFRAIL study. Serum levels of 14 inflammatory proteins, including cytokines, growth factors, and acute phase proteins, were measured at baseline. Almost 20 % of the participants had a significant global functional decline over time. Interleukin (IL)-6 serum levels were uniquely positively associated with global functional decline, even after correcting for multiple confounders (odds ratio 1.51). Odds ratios for the individual aspects (physical dependency, physical performance, cognition, and depression) of functioning were lower, and composite scores of physical or mental decline were not significant. The proportion of global functional decline exhibited a dose-response curve with increasing levels of IL-6. Thus, IL-6 is an independent risk indicator for accelerated global functional decline in the oldest old. Our results suggest that simple serum levels of IL-6 may be very useful in short-term identification or evaluation of global functional status in the oldest old.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Value Of Crp and Other Inflammatory Markersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study

Adriaensen

Matheï

Vaes

et al. 2014

AGE

View full text Add to dashboard Cite

show abstract

“…For example, in a retrospective analysis of the phase 3 AGO-OVAR 3 study (Carboplatin/Paclitaxel compared to Cisplatin/Paclitaxel in the first-line setting following cytoreductive surgery for advanced ovarian cancer), 103 patients over the age of 70 were compared to the under 70 years group (n=676). Over 80% of the patients in this analysis were ECOG PS 0 or 1 and the mean age of patients over 70 was 73.5 (range [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85]. The authors concluded that combination chemotherapy was tolerable in an older population but discontinuation rates were double in those over the age of 70 compared to the <70 group [40].…”

Section: (Ii) Chemotherapymentioning

confidence: 99%

Improving outcomes for older women with gynaecological malignancies

Dumas

Ring

Butler

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

The incidence of most gynaecological malignancies rises significantly with increasing age. With an ageing population, the proportion of women over the age of 65 with cancer is expected to rise substantially over the next decade. Unfortunately, survival outcomes are much poorer in older patients and evidence suggests that older women with gynaecological cancers are less likely to receive current standard of care treatment options. Despite this, older women are underrepresented in practice changing clinical studies. The evidence for efficacy and tolerability is therefore extrapolated from a younger; often more fit population and applied to in every day clinical practice to older patients with co-morbidities. There has been significant progress in the development of geriatric assessment in oncology to predict treatment outcomes and tolerability however there is still no clear evidence that undertaking a geriatric assessment improves patient outcomes. Clinical trials focusing on treating older patients are urgently required. In this review, we discuss the evidence for treatment of gynaecological cancers as well as methods of assessing older patients for therapy. Potential biomarkers of ageing are also summarised.

show abstract

“…20,21 High levels of IL-6 have been associated with worse cross-sectional cognitive performance and cognitive decline. 22,23 Low levels of serum albumin have been cross-sectionally associated with cognitive impairment in older adults, and there is evidence that serum albumin may have a role in reducing b-amyloid toxicity. 24,25 Nearly all of the markers used in this analysis were measured in the entire Health ABC cohort, although plasma b-amyloid was measured in a subset of 998 participants (random sample of race and sex) who had more than one cognitive test measure.…”

mentioning

confidence: 99%

Development and validation of risk index for cognitive decline using blood-derived markers

et al. 2015

View full text Add to dashboard Cite

Objective: We sought to develop and validate a risk index for prospective cognitive decline in older adults based on blood-derived markers. Methods:The index was based on 8 markers that have been previously associated with cognitive aging: APOE genotype, plasma b-amyloid 42/40 ratio, telomere length, cystatin C, glucose, C-reactive protein, interleukin-6, and albumin. The outcome was person-specific cognitive slopes (Modified Mini-Mental State Examination) from 11 years of follow-up. A total of 1,445 older adults comprised the development sample. An index based on dichotomized markers was divided into low-, medium-, and high-risk categories; the risk categories were validated with the remaining sample (n 5 739) using linear regression. Amyloid was measured on a subsample (n 5 865) and was included only in a secondary index. Results:The risk categories showed significant differences from each other and were predictive of prospective cognitive decline in the validation sample, even after adjustment for age and baseline cognitive score: the low-risk group (24.8%) declined 0.

show abstract

Circulating interleukin‐6 concentration and cognitive decline in old age: the PROSPER study

Abstract: Abstract. Mooijaart SP, Sattar N, Trompet S, Lucke J, Stott DJ, Ford I, Jukema JW, Westendorp RGJ, de Craen AJM, on behalf of The PROSPER Study

Cited by 98 publications

References 22 publications

Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study

Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study

Improving outcomes for older women with gynaecological malignancies

Development and validation of risk index for cognitive decline using blood-derived markers

Contact Info

Product

Resources

About